Navigation Links
Quanterix Appoints Paul Chapman as President and Chief Executive Officer
Date:7/20/2012

LEXINGTON, Mass., July 20, 2012 /PRNewswire/ -- Quanterix Corporation, developer of the Single Molecule Array (Simoa) technology, announced today that it has appointed Paul Chapman as its new President and Chief Executive Officer.  Mr. Chapman joins the company at a pivotal time, as it moves from development to commercialization of its revolutionary digital ELISA platform that improves conventional immunoassay sensitivity 1000-fold.

"Quanterix's Simoa technology has the potential to dramatically change the world of biomarker research and clinical diagnostics," says Chapman.   "I am very excited to work with the exceptional team at Quanterix to make that potential a reality in the near future."

Prior to joining Quanterix, Mr. Chapman was Vice President of the BioPharm Process Solutions business at EMD Millipore where he was responsible for the Marketing and R&D teams in the $800 million business.   Prior to joining Millipore, he was the Vice President, Hospital Solutions for Roche Near Patient Testing in Austria, where he held P&L responsibility for Roche's decentralized Cardiac, Blood Gas / Electrolyte and Hospital Glucose businesses.  Mr. Chapman was also the International Business Development Manager at Roche Molecular Diagnostics for blood screening and, prior to that, held an array of sales and marketing positions at Roche Diagnostics Canada (where he began his career in 1993) focused primarily in the Molecular Diagnostics field.  Mr Chapman has a B.Sc. in Microbiology from the University of Western Ontario, a B.Sc (hons) in Immunology from the University of Guelph Ontario, and graduated from the Marketing Management Program (MMP) from the Richard Ivy School of Business.

"Paul is a visionary leader with a strong track record in several businesses and I have great confidence that he will make Quanterix a huge success," says Martin Madaus, Executive Chairman of the Board of Directors. "His background and capabilities to bring new technologies to market successfully make him uniquely qualified for Quanterix."  

Dr. Martin Madaus, who was previously CEO and Executive Chairman of the Board of Directors, will continue at Quanterix as the Executive Chairman, while Mr. Chapman takes the reins of the company's operations as President and Chief Executive Officer to prepare the organization for the launch of its first product in 2013. 

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
2. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
3. C3i Appoints Jonathan Song to Business Development Executive in Asia
4. Organovo Holdings Appoints James T. Glover to Board of Directors
5. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
6. ReShape Medical Appoints Robert E. Grant to Board of Directors
7. Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
8. Stereotaxis Appoints William C. Mills III as Chairman of Board of Directors
9. Gentech Pharmaceutical Appoints New Medical Director for PhenTabz/ADDTabz
10. GenVec Appoints Cynthia Collins as President and CEO
11. Accuray Appoints Richard Pettingill, LFACHE to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The global fluoropolymer market in the healthcare industry ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, ... from industry experts. The report covers the market landscape and its ...
(Date:1/17/2017)... --  Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today ... and pharmaceutical development at Tocagen, will present at Phacilitate Cell ... in Miami . Details of ... ... viruses - what to do when and why Date and Time: ...
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), ... report to their offering. ... The global active pharmaceutical ingredients market is expected to ... 2016, growing at a CAGR of 6.3% from 2016 to 2021. ...
Breaking Medicine Technology:
(Date:1/17/2017)... Chicago, Illinois (PRWEB) , ... January 17, 2017 , ... ... Antonio Breast Cancer Symposium (SABCS) or those who desire a more intimate review and ... Antonio: Breast Cancer – Bench to Bedside—is being offered by Imedex on February 4, ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Healthful-Flex. , The company, owned and operated by Ed Stroup, was created ... reasonable price with the highest level of customer service. Healthful Balance products can ...
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Mirror Mirror ... earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, ... part of this elite group of providers. , Produced by Zeltiq, CoolSculpting is ...
Breaking Medicine News(10 mins):